BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

Oncotarget

Volumn 6, Issue 19, 2015, Pages 17698-17712

  Coudé, Marie Magdelaine ^a,b   Braun, Thorsten ^a,b   Berrou, Jeannig ^a   Dupont, Mélanie ^a   Bertrand, Sibyl ^a   Masse, Aline ^a   Raffoux, Emmanuel ^a,b   Itzykson, Raphaël ^a,b   Delord, Marc ^a   Riveiro, Maria E ^c   Herait, Patrice ^d   Baruchel, André ^a,e   Dombret, Hervé ^a,b   Gardin, Claude ^a,b  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Oncology Therapeutic Development   (France)

^d Oncoethix   (Switzerland)

^e HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Acute leukemias; BET inhibitors; c MYC; HEXIM1; OTX015

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; AZACITIDINE; BROMODOMAIN 2 PROTEIN; BROMODOMAIN 3 PROTEIN; BROMODOMAIN 4 PROTEIN; CASPASE 3; CELL PROTEIN; CYTOCHROME C; HEXIM1 PROTEIN; MYC PROTEIN; PANOBINOSTAT; UNCLASSIFIED DRUG; ACETANILIDE DERIVATIVE; ANTINEOPLASTIC AGENT; BIRABRESIB; BRD2 PROTEIN, HUMAN; BRD3 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; HEXIM1 GENE; HUMAN; HUMAN CELL; IC50; MALE; ONCOGENE C MYC; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL CYCLE; DNA MICROARRAY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; LEUKEMIA; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ACETANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMMUNOBLOTTING; LEUKEMIA; MALE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84938249789     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4131     Document Type: Article

References (40)

1. Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ and Luthra R. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. The Journal of molecular diagnostics : JMD. 2011; 13:678-686.
2. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011; 478:524-528.
3. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012; 120:2843-2852.
4. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146:904-917.
5. Emadali A, Rousseaux S, Bruder-Costa J, Rome C, Duley S, Hamaidia S, Betton P, Debernardi A, Leroux D, Bernay B, Kieffer-Jaquinod S, Combes F, Ferri E, McKenna CE, Petosa C, Bruley C, et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO molecular medicine. 2013; 5:1180-1195.
6. Yang Z, Zheng C, Thiriet C and Hayes JJ. The core histone N-terminal tail domains negatively regulate binding of transcription factor IIIA to a nucleosome containing a 5S RNA gene via a novel mechanism. Molecular and cellular biology. 2005; 25:241-249.
7. Bisgrove DA, Mahmoudi T, Henklein P and Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:13690-13695.
8. Nechaev S and Adelman K. Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation. Biochimica et biophysica acta. 2011; 1809:34-45.
9. Zhou Q and Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiology and molecular biology reviews : MMBR. 2006; 70:646-659.
10. Dey A, Chao SH and Lane DP. HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell cycle. 2007; 6:1856-1863.
11. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ and Zhou Q. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Molecular cell. 2003; 12:971-982.
12. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA and Young RA. c-Myc regulates transcriptional pause release. Cell. 2010; 141:432-445.
13. French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR and Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer research. 2003; 63:304-307.
14. Huang B, Yang XD, Zhou MM, Ozato K and Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Molecular and cellular biology. 2009; 29:1375-1387.
15. Gurumurthy M, Tan CH, Ng R, Zeiger L, Lau J, Lee J, Dey A, Philp R, Li Q, Lim TM, Price DH, Lane DP and Chao SH. Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. Journal of molecular biology. 2008; 378:302-317.
16. Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014; 28:311-320.
17. Blobel GA, Kalota A, Sanchez PV and Carroll M. Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. Cancer cell. 2011; 20:287-288.
18. LeRoy G, Rickards B and Flint SJ. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Molecular cell. 2008; 30:51-60.
19. Romesser PB, Perlman DH, Faller DV, Costello CE, McComb ME and Denis GV. Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. The American journal of pathology. 2009; 175:25-35.
20. Garnier JM, Sharp PP and Burns CJ. BET bromodomain inhibitors: a patent review. Expert opinion on therapeutic patents. 2014; 24:185-199.
21. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011; 478:529-533.
22. Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014; 123:697-705.
23. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI and Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153:320-334.
24. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH and Eick D. The transcriptional program of a human B cell line in response to Myc. Nucleic acids research. 2001; 29:397-406.
25. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics. 2000; 25:25-29.
26. Estey E and Dohner H. Acute myeloid leukaemia. Lancet. 2006; 368:1894-1907.
27. Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM, Aserlind AB, Wang H, Evan GI, Kluk MJ, Bradner JE, Aster JC and French CA. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene. 2014; 33:1736-1742.
28. Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE and Frank DA. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Molecular cancer therapeutics. 2014; 13:1194-1205.
29. Diribarne G and Bensaude O. 7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor. RNA biology. 2009; 6:122-128.
30. Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Mullauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J and Valent P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012; 3:1588-1599.
31. Valent P and Zuber J. BRD4: a BET(ter) target for the treatment of AML? Cell cycle. 2014; 13:689-690.
32. Chen C, Liu Y, Lu C, Cross JR, Morris JPt, Shroff AS, Ward PS, Bradner JE, Thompson C and Lowe SW. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes & development. 2013; 27:1974-1985.
33. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J and Lowe SW. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer cell. 2014; 25:652-665.
34. Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Dohner K, Beverloo HB, Bradner JE, Dohner H, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014; 157:369-381.
35. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30:4515-4523.
36. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nature genetics. 2014; 46:364-370.
37. Montalban-Bravo G and Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2014.
38. Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, Rappaport AR, Atadja P, Lowe SW and Johnstone RW. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood. 2014; 123:1341-1352.
39. Benjamini Y, Drai D, Elmer G, Kafkafi N and Golani I. Controlling the false discovery rate in behavior genetics research. Behavioural brain research. 2001; 125:279-284.
40. Reynolds CP and Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. Methods in molecular medicine. 2005; 110:173-183.